These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22136227)

  • 1. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of Bcr-Abl coiled coil oligomerization by design.
    Dixon AS; Pendley SS; Bruno BJ; Woessner DW; Shimpi AA; Cheatham TE; Lim CS
    J Biol Chem; 2011 Aug; 286(31):27751-60. PubMed ID: 21659527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.
    Constance JE; Woessner DW; Matissek KJ; Mossalam M; Lim CS
    Mol Pharm; 2012 Nov; 9(11):3318-29. PubMed ID: 22957899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
    Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
    Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML.
    Lima MCP; Hornsby BD; Lim CS; Cheatham TE
    J Phys Chem B; 2024 Jul; 128(27):6476-6491. PubMed ID: 38951498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
    Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
    Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.
    Miller GD; Woessner DW; Sirch MJ; Lim CS
    Mol Pharm; 2013 Sep; 10(9):3475-83. PubMed ID: 23915432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
    Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
    Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
    Bruno BJ; Lim CS
    Mol Pharm; 2015 May; 12(5):1412-21. PubMed ID: 25858426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
    Cornillie SP; Bruno BJ; Lim CS; Cheatham TE
    J Phys Chem B; 2018 Apr; 122(14):3864-3875. PubMed ID: 29519125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colocalization of USP1 and РН domain of Bcr­Abl oncoprotein in terms of cronic myeloid leukemia cell rearrangements.
    Antonenko SV; Gurianov DS; Тelegeev GD
    Tsitol Genet; 2016; 50(4):11-5. PubMed ID: 30480413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell.
    Liu X; Li Y; Wen L; Tao K; Xiao Q; Cao W; Huang Z; Gao M; Li H; Wang F; Feng W
    Cancer Lett; 2015 Dec; 369(1):222-8. PubMed ID: 26321052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
    Huang ZL; Gao M; Li QY; Tao K; Xiao Q; Cao WX; Feng WL
    Oncotarget; 2013 Dec; 4(12):2249-60. PubMed ID: 24158537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
    Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
    Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
    Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS
    Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
    Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.